Toggle navigation
Home
Search
Services
Blog
Contact
About
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
University of Minnesota Twin Cities, Minneapolis, MN, United States
Search grants from University of Minnesota Twin Cities
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Redesign Rat Model for ALS Research
Exercise and Anxiety in Adults with Arthritis: An IVHet Meta-Analysis
Prediction Model: Breast Cancer in Women Irradiated for a Pediatric Malignancy
Genetic Analysis of S. aureus Capsule Production
REU Site: Molecular Biophysics
Recently added grants:
An Imputation-Consistency Algorithm for Biomedical Complex Data Analysis
Development of a Structurally Interacting RNA (sxRNA) technology
Macromolecular dynamics and conformational changes in biological function
Administrative Core
Evolutionary and functional genomics of genetic novelties and expression adaptation in Drosophila
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN015000-001
Application #
6994812
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2004
Total Cost
Indirect Cost
Institution
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Related projects
NIH 2006
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
NIH 2004
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
Publications
Rosas, R R; Cole, K A; Darrah, L et al.
(2012)
A comparison of screening methods in two early phase oral leukoplakia clinical trials.
Oral Dis 18:720-3
Comments
Be the first to comment on this grant